A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)
A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Concurrent Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)
This is a Phase I/II, single-arm, open-label, exploratory study aimed at evaluating the safety, tolerability, and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with gemcitabine and iparomlimab-toripalimab in patients with borderline resectable pancreatic cancer. The study is divided into two phases: The Phase Ib dose-escalation phase will use a "3+3" design to explore the maximum tolerated dose (MTD) of SBRT (6 Gy×5 F, 7 Gy×5 F, 8 Gy×5 F) combined with gemcitabine and iparomlimab-toripalimab. The Phase II phase will further evaluate the efficacy and safety of this combination regimen based on the SBRT dose determined in Phase Ib. The primary efficacy endpoint is the R0 resection rate.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is a single-center, Phase I/II, single-arm, open-label, exploratory clinical study initiated by Tianjin Medical University Cancer Institute & Hospital.
Phase Ib (Dose-Escalation Phase): A classic "3+3" design will be used to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of SBRT. Three pre-specified SBRT dose levels are planned: 6 Gy×5 F, 7 Gy×5 F, and 8 Gy×5 F. All subjects will concurrently receive standard-dose gemcitabine chemotherapy and iparomlimab-toripalimab immunotherapy. The DLT observation period is 6 months from the start of treatment, focusing on Grade 3 or higher SBRT-related toxicities in organs at risk. The MTD is defined as the highest dose level at which ≤33% (i.e., no more than 1 out of 6) of subjects experience a DLT during the observation period.
Phase II (Expansion Phase): Based on the SBRT MTD determined in Phase Ib, preoperative neoadjuvant therapy will be administered in combination with gemcitabine and iparomlimab-toripalimab. The treatment cycle consists of 3 cycles, expected to last 12 weeks. Tumor assessment will be performed after 2 cycles of treatment. If there is no disease progression and adverse reactions are tolerable, treatment will continue. Surgical resection will be performed 3-4 weeks after the last dose of chemotherapy and immunotherapy. Postoperatively, if the investigator determines the patient may benefit, adjuvant therapy will be administered, consisting of 4 cycles of gemcitabine chemotherapy and maintenance immunotherapy with iparomlimab-toripalimab for up to 1 year. The primary endpoint is the R0 resection rate.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Maobin Meng(Co-Principal Investigator), PhD
- Telefonnummer: 15202231270
- E-post: mmeng@tmu.edu.cn
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥18 years and ≤75 years, both genders.
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
- Radiographically assessed as borderline resectable pancreatic cancer according to NCCN guidelines.
- At least one measurable lesion per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ and bone marrow function.
- Expected survival ≥ 6 months.
- Voluntarily signed informed consent form.
Exclusion Criteria:
- Known distant metastases.
- Prior systemic anti-tumor therapy or radiotherapy for pancreatic cancer.
- Active autoimmune disease requiring systemic treatment within the past 2 years.
- History of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, non-melanoma skin cancer, or superficial bladder tumor.
- Uncontrolled comorbid conditions, including but not limited to active infections, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- Pregnant or lactating women.
- Any condition that, in the investigator's opinion, would make the subject unsuitable for participation in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Iparomlimab-Tuvonralimab + Gemcitabine Group
Participants will receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1) combined with Gemcitabine (1000 mg/m², IV, D1 and D8) every 3 weeks for up to 6 cycles. After 6 cycles, participants without disease progression and with acceptable tolerance may continue to receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1, every 3 weeks) as maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or study termination. |
Iparomlimab/Tuvonralimab (Code: QL1706) is a bispecific antibody targeting PD-1 and CTLA-4. It is administered by intravenous infusion at a dose of XX mg/kg once every 3 weeks until disease progression or unacceptable toxicity. Gemcitabine (Brand name: Gemzar) is a nucleoside analogue chemotherapeutic agent. It is administered by intravenous infusion at a dose of 1000 mg/m² on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. SBRT is a highly precise form of radiation therapy that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues. It is administered in XX fractions over XX days/weeks. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate, ORR
Tidsramme: From first dose to disease progression or study completion, up to approximately 24 months
|
Objective Response Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR) or partial response (PR). |
From first dose to disease progression or study completion, up to approximately 24 months
|
|
Incidence of Adverse Events
Tidsramme: From first dose to 90 days after last dose, up to approximately 27 months
|
Incidence and severity of adverse events assessed by CTCAE v5.0, including treatment-related adverse events (TRAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs). |
From first dose to 90 days after last dose, up to approximately 27 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease Control Rate, DCR
Tidsramme: From first dose to disease progression or study completion, up to approximately 24 months
|
Disease Control Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR), partial response (PR), or stable disease (SD). |
From first dose to disease progression or study completion, up to approximately 24 months
|
|
Progression-Free Survival, PFS
Tidsramme: From first dose to disease progression or death, up to approximately 24 months
|
Progression-Free Survival assessed by RECIST v1.1, defined as the time from first dose to the first documentation of disease progression or death from any cause. |
From first dose to disease progression or death, up to approximately 24 months
|
|
Overall Survival, OS
Tidsramme: From first dose to death or last follow-up, up to approximately 36 months
|
Defined as the time from first dose to death from any cause. |
From first dose to death or last follow-up, up to approximately 36 months
|
|
Duration of Response, DOR
Tidsramme: From first documentation of response to disease progression or death, up to approximately 24 months
|
Duration of Response assessed by RECIST v1.1, defined as the time from the first documentation of complete response (CR) or partial response (PR) to the first documentation of disease progression or death from any cause. |
From first documentation of response to disease progression or death, up to approximately 24 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlation between Biomarkers and Clinical Efficacy
Tidsramme: From first dose to study completion, up to approximately 36 months
|
To explore the correlation between biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI) status in tumor tissue and clinical efficacy endpoints including ORR, PFS, and OS. |
From first dose to study completion, up to approximately 36 months
|
|
Quality of Life Assessment
Tidsramme: From baseline to 90 days after last dose, up to approximately 27 months
|
To evaluate changes in quality of life during and after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). |
From baseline to 90 days after last dose, up to approximately 27 months
|
|
Dynamic Changes of Peripheral Blood Immune Cell Subsets and Cytokines
Tidsramme: From first dose to disease progression or study completion, up to approximately 24 months
|
To explore the dynamic changes of peripheral blood immune cell subsets (CD3+, CD4+, CD8+ T cells, etc.) and cytokines (IL-6, TNF-α, IFN-γ, etc.) during treatment and their correlation with efficacy and adverse events. |
From first dose to disease progression or study completion, up to approximately 24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- TJSPAC-03
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
This is a prospective, single-arm, single-center Phase II clinical study to evaluate the efficacy and safety of Iparomlimab/Tuvonralimab combined with gemcitabine in the treatment of locally advanced pancreatic cancer. The study plans to enroll 30 patients with histologically or cytologically confirmed locally advanced pancreatic ductal adenocarcinoma. Subjects will receive Iparomlimab/Tuvonralimab combined with gemcitabine until disease progression, intolerable toxicity, withdrawal of informed consent, or completion of 6 cycles of treatment. The primary endpoint is objective response rate (ORR), and secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .